您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Succinobucol(AGI-1067)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Succinobucol(AGI-1067)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Succinobucol(AGI-1067)图片
CAS NO:216167-82-7
规格:98%
分子量:616.91
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议

产品介绍
Succinobucol是一种酚类抗氧化剂,具有抗炎、抗血小板聚集的作用。
CAS:216167-82-7
分子式:C35H52O5S2
分子量:616.91
纯度:98%
存储:Store at -20°C

Background:

Succinobucol is a phenolic antioxidant with anti-inflammatory and antiplatelet effects.


Succinobucol (10, 50, 100 μM) causes a dose-dependent reduction in collagen-induced platelet aggregation in rabbit whole blood. Succinobucol also causes a significant reduction in whole blood aggregation in response to ADP. Succinobucol (10, 100 μM) significantly lowers the relaxation to X/XO[1]. Succinobucol significantly prevents 3-NP-induced loss of SH-SY5Y cell viability, generation of reactive oxygen species, and decrease of δΨm. Succinobucol does not protect against 3-NP-induced inhibition of mitochondrial complex II activity, pointing to the mitigation of secondary events resultant from mitochondrial complex II inhibition. Succinobucol significantly increases (50 %) the levels of GSH in SH-SY5Y cells, which is paralleled by significant increases in glutamate cysteine ligase messenger RNA (mRNA) expression and activity[2]. Succinobucol effectively exhibits superior inhibitory effects on cell migration and invasion activities, VCAM-1 expression and cell-cell binding of RAW 264.7 to 4T1 cells. Succinobucol also shows inhibitory effect on VCAM-1 expression in 4T1 cells and cell-cell binding of RAW 264.7 to 4T1 cancer cells[3].


Succinobucol (50, 100, and 150 mg/kg, i.v.) has no significant effect on either heart rate or MAP, but the blood removed 15 minutes after the final injection of succinobucol shows significantly less aggregation in response to collagen at both 5 µg/mL and 20 µg/mL in rats[1]. Succinobucol (40 mg/kg) by tail injection significantly reduces the average number of metastatic nodules in lung metastatic breast cancer mice[3].


[1]. Houston SA, et al. An investigation of the antiplatelet effects of succinobucol (AGI-1067). Platelets. 2017 May;28(3):295-300. [2]. Colle D, et al. Succinobucol, a Lipid-Lowering Drug, Protects Against 3-Nitropropionic Acid-Induced Mitochondrial Dysfunction and Oxidative Stress in SH-SY5Y Cells via Upregulation of Glutathione Levels and Glutamate Cysteine Ligase Activity. Mol Neurobiol. 2016 Mar;53(2):1280-95. [3]. Dan Z, et al. A pH-Responsive Host-guest Nanosystem Loading Succinobucol Suppresses Lung Metastasis of Breast Cancer. Theranostics. 2016 Jan 25;6(3):435-45.